https://www.selleckchem.com/products/cc-122.html
G9a histone methyltransferase exerts oncogenic effects in several tumor types and its inhibition promotes anticancer effects. However, the impact on checkpoint inhibitor blockade response and the utility of G9a or its target genes as a biomarker is poorly studied. We aimed to examine whether G9a inhibition can augment the efficacy of checkpoint inhibitor blockade and whether , a G9a target gene, can predict treatment response. Clinical potential of LC3B as a biomarker of checkpoint inhibitor blockade was assessed using patient samples in
Aimer
Commentaire
Partagez
